DNA damage response inhibitors enhance tumour treating fields (TTFields) potency in glioma stem-like cells.

To our knowledge, our findings represent the first report of TTFields applied with clinically approved or in-trial DDRi in GSC models and provides a basis for translational studies toward multimodal DDRi/TTFields-based therapeutic strategies for patients with these currently incurable tumours.